Genome-Scale CRISPRa Screen Identifies Novel Factors for Cellular Reprogramming. by Yang, Jian et al.
Stem Cell Reports
 




Article Type: Research Article
Keywords: CRISPR/Cas9;  CRISPR activation;  Epiblast Stem cells;  reprogramming;  Genome-
wide screen;  Activation screen;  Mouse;  Gain-of-function;  CRISPR screen;
Reprogramming pathways;  induced pluripotent stem cells;  Embryonic stem cells
Corresponding Author: Emmanouil Metzakopian, Ph.D
Cambridge university
Cambridge, UNITED KINGDOM
First Author: Emmanouil Metzakopian, Ph.D
Order of Authors: Emmanouil Metzakopian, Ph.D
Jian Yang, Ph. D
Sandeep Sundara Rajan, Ph. D
Mathias Friedrich, M.D
Guocheng Lan, Ph. D
Xiangang Zou, Ph. D
Hannes Ponstingl, Ph. D
Dimitrios Garyfallos
Pentao Liu, Ph. D
Allan Bradley, Ph. D
Abstract: Primed epiblast stem cells (EpiSCs) can be reverted to a pluripotent embryonic stem
cell (ESC) like state by the expression of single reprogramming factors such as Klf4
and Nanog. To date, only a few genes have been shown to be able to return EpiSCs to
pluripotency and their molecular mechanisms are not fully understood. We used
CRISPRa to perform a genome-scale, gain of function (GoF) reprogramming screen in
EpiSCs. We identified 142 candidates, amongst them known reprogramming factors
such as Oct4, Nanog, Klf2 and Nr5a2 and validated 50 novel genes, of which we
chose Sall1 for further investigation. We show that Sall1 augments reprogramming of
mouse embryonic fibroblasts as well and that these induced pluripotent stem cells are
indeed fully pluripotent including the formation of chimeric mice. In addition, we
demonstrate that Sall1 synergises with Nanog in re-programming and that
overexpression in ESCs delays their conversion from naïve ESCs to primed EpiSCs by
keeping them in a formative state. Using RNA-seq, we identify and validate Klf5 and
Fam189a2 as new downstream targets of Sall1 and Nanog. In summary, our study
identifies a number of novel candidates that potentially play a role in EpiSC
reprogramming and provides new insights into molecular mechanisms of the transition
between naïve and primed states. This work demonstrates the power of using CRISPR
technology in understanding complex processes such as reprogramming.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
1 
 
Genome-scale CRISPRa screen identifies 
novel factors for cellular reprogramming 
 
Jian Yang‡⊥+, Sandeep S Rajan‡†+, Mathias J Friedrich‡+, Guocheng Lan¶, Xiangang Zou¶, 
Hannes Ponstingl‡, Dimitrios A Garyfallos‡, Pentao Liu‡¢, Allan Bradley‡, and Emmanouil 
Metzakopian‡†*  
‡Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, 
UK 
†UK Dementia Research Institute, Department of Clinical Neuroscience, University of 
Cambridge, CB2 0AH, UK 
¶Cancer Research UK, Cambridge Institute, Li Ka Shing Centre, University of Cambridge, 
Cambridge, CB2 0RE, UK 
¢School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, Stem Cell and Regenerative 
Medicine Consortium, University of Hong Kong, Hong Kong, China 
⊥Current address: Key Laboratory of Arrhythmias, Ministry of Education, Shanghai East 
Hospital, Tongji University School of Medicine, Shanghai 200120, China  
+These authors contributed equally to the work. 
*Correspondence should be addressed to:  
Emmanouil Metzakopian 
UK Dementia Research Institute  
Cambridge Biomedical Campus 
University of Cambridge 






Primed epiblast stem cells (EpiSCs) can be reverted to a pluripotent embryonic stem 
cell (ESC) like state by the expression of single reprogramming factors such as Klf4 
and Nanog. To date, only a few genes have been shown to be able to return EpiSCs 
to pluripotency and their molecular mechanisms are not fully understood. We used 
CRISPRa to perform a genome-scale, gain of function (GoF) reprogramming screen 
in EpiSCs. We identified 142 candidates, amongst them known reprogramming factors 
such as Oct4, Nanog, Klf2 and Nr5a2 and validated 50 novel genes, of which we chose 
Sall1 for further investigation. We show that Sall1 augments reprogramming of mouse 
embryonic fibroblasts as well and that these induced pluripotent stem cells are indeed 
fully pluripotent including the formation of chimeric mice. In addition, we demonstrate 
that Sall1 synergises with Nanog in reprogramming and that overexpression in ESCs 
delays their conversion from naïve ESCs to primed EpiSCs by keeping them in a 
formative state. Using RNA-seq, we identify and validate Klf5 and Fam189a2 as new 
downstream targets of Sall1 and Nanog. In summary, our study identifies a number of 
novel candidates that potentially play a role in EpiSC reprogramming and provides 
new insights into molecular mechanisms of the transition between naïve and primed 
states. This work demonstrates the power of using CRISPR technology in 





The ability of pluripotent stem cells (PSCs) to self-renew and their potential to 
differentiate into multiple cell types makes them potentially useful for clinical 
applications 1,2. PSCs can either be derived from early embryos or be induced by 
reprogramming somatic cells with Yamanaka factors i.e., Oct4, Sox2, c-Myc and Klf4 
amongst other transcription factors, mRNAs, microRNAs and small molecules 3-6. 
These PSCs are referred to as induced pluripotent stem cells (iPSCs). During early 
mouse embryo development, at least two types of PSCs can be derived, naïve 
embryonic stem cells (ESCs) from the inner mass of the blastocyst and primed post-
implantation epiblast stem cells (EpiSCs) 7-10. While both have the potential to 
differentiate into multiple lineages, only ESCs can contribute extensively to chimeras, 
showing unbiased developmental potential. Both ESCs and EpiSCs express major 
pluripotent transcription factors such as Oct4 and Sox2 at similar levels. In EpiSCs 
however, reduced expression of pluripotency-associated factors such as Rex1 and 
Klf4 and elevated levels of early differentiation markers like Fgf5, Gata6 and Otx2 
indicate their restricted developmental potential. Interestingly, EpiSCs cultured in fully 
defined ESC medium (with selective inhibition of mitogen-activated protein kinase and 
glycogen synthase kinase 3 and Leukemia Inhibitory Factor (LIF); 2i/LIF medium) can 
be reprogrammed into ESCs by over-expressing single gene such as Nanog, Klf4 or 
Nr5a211. Therefore, EpiSCs are a useful model to identify novel reprogramming factors 
through genetic screens. 
Recently, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and 
its associated protein, Cas9, has gained importance by achieving simple, precise and 
rapid editing of the genome, enabling large scale experiments such as genetic 
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screening. While the RNA-programmable (single guide RNA, sgRNA) endonuclease 
Cas9 is used to induce double-strand breaks in defined genomic locations, its 
catalytically dead variant (dCas9) can be fused with transcriptional activators and 
directed towards promoter regions to increase gene expression (CRISPR activation, 
CRISPRa) 12,13. 
Genome-wide screening is a powerful unbiased approach to discover genes and 
pathways that underlie biological processes. To date, the identification of key 
transcription factors and epigenetic modifiers within naïve and primed PSCs has been 
investigated by employing either gain-of-function (GoF) screens using cDNA libraries 
and PiggyBac transposons or loss-of-function (LoF) screens using or RNA 
interference 14-16. 
Here, we describe the development and application of a genome-scale CRISPRa 
screen to identify genes that contribute to mouse EpiSC reprogramming. We show 
that our screening approach not only detects established reprogramming factors such 
as Oct4 and Nanog, but also identifies novel candidate genes. We focus on the role 
of Sall1, a transcription factor belonging to the Spalt-like gene family, which has been 
implicated in cellular reprogramming in a number of studies but has not been 
sufficiently investigated17-20. Our work substantiates Sall1 as a potent reprogramming 
gene candidate by demonstrating its ability to reprogram EpiSCs and mouse 
embryonic fibroblasts (MEFs) to iPSCs. In addition, we show that Sall1 may exert its 






GoF CRISPRa screen identifies novel reprogramming genes 
As a first step towards a genome-scale CRISPRa reprogramming screen, we sought 
to determine the optimal Cas9 transactivation system, as several variants have been 
published21-26. To that end, we created PiggyBac-transposable expression vectors 
with a Blasticidin-mCherry cassette for four different dCas9-CRISPRa systems: 
dCas:VP160, dCas9:SunTag, dCas9:VPR and dCas9:SAM (synergistic activation 
mediator, Supplementary Figure 1).  
Furthermore, we designed a versatile sgRNA expression construct (pKLV-PB-U6-
gRNA-PGK-Puro-T2A-TagBFP)27 harbouring a Puromycin selection cassette with a 
blue fluorescent protein (BFP) marker (Supplementary Figure 1), which can be stably 
integrated into target genomes either as Lentivirus or via PiggyBac mediated 
transposition. 
Using these vectors and single guides directed against the promoter region of two 
genes with low baseline expression, Ascl1 and Neurog2, we sought to find the most 
potent CRISPR activation system. After stable integration of dCas9-CRISPRa and the 
sgRNA-vectors into HEK293 cells via transposition and antibiotic selection, RT-qPCR 
revealed that dCas9:SAM achieved the highest overexpression of both target genes 
and thus was chosen as CRISPRa system for all other experiments (Figure 1a). 
To perform a genome-scale activation screen, we designed a pooled library of 87,863 
sgRNAs targeting a 250 bp region upstream of the transcription start site (TSS) of 




We decided to use EpiSC derived from Oct4-GFP reporter transgenic mice as they 
have been used for this purpose before28. Characteristically for EpiSCs these cells 
already exhibit a baseline Oct4 (and therefore GFP) expression. However, only cells 
successfully reprogrammed to the naïve pluripotent state are able to maintain and 
increase Oct4 expression upon plating in medium containing Leukemia Inhibitory 
Factor (LIF), with selective inhibitors against mitogen-activated protein kinase and 
glycogen synthase kinase 3; (2i), hereafter 2i/LIF medium. Thus, successfully 
reprogrammed Oct4-GFP EpiSCs can be identified by their strong GFP expression 
(Supplementary Figure 2a) and the characteristic ESC-like morphology, and grow as 
distinct colonies, whereas EpiSCs failing to reprogram either detach and die or 
differentiate.  
For the screen, we first generated Oct4-GFP EpiSCs expressing dCas9:SAM using 
PiggyBac transposase mediated stable integration of our dCas9:SAM-Blasticidine 
cassette and antibiotic selection. We then transduced 100 x 106 dCas9:SAM 
expressing EpiSCs with our sgRNA expression construct containing the library at a 
multiplicity of infection (MOI) of 0.3 (Supplementary Figure 2b). Two days later, we 
FACS-sorted 10 x 106 successfully transduced cells by BFP expression, giving a 
library coverage of around 114-fold. These BFP+ cells were seeded in 2i/LIF medium 
to select for reprogramming cells. After 14-16 days of culture in 2i/LIF, 480 GFP+ 
colonies were harvested for expansion (Figure 1c). Next generation sequencing 
revealed 146 sgRNAs targeting 142 different genes (Supplementary Table 6). These 
included known reprogramming factors Nanog29,30, Klf231 and Nr5a211, confirming the 
specificity of the screen. 
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GOTERM analysis on these 142 genes identified an enrichment in pathways related 
to transcriptional activation, expression of various transcription factors and enrichment 
towards stem cell maintenance (Figure 1d). 
To validate these candidate genes individually, we chose the highest performing 
sgRNA for each from the library, including Nanog as a positive control and again 
transduced dCas9:SAM expressing Oct4-GFP EpiSCs. We expected the validation 
rate to be no higher than 50%, as small scale single colony sub-sampling showed an 
average of 2 sgRNAs present in most colonies (data not shown), where one sgRNA 
presumably acts as the driver responsible for reprogramming while the other is co-
amplified as a passenger. After plating and culture in 2i/LIF medium as before, GFP+ 
ESC-like colonies could be observed for Oct4, Nanog and 52 of the candidate genes, 
resulting in a 36 % validation rate (Supplementary Table 7). The efficiency of 
reprogramming was gene dependent ranging from 5 to 165 colonies per 1 x 106 cells 
transfected (Figure 1e). Amongst the genes with the highest colony counts were our 
positive controls Nanog and one of the Yamanaka factors Oct4, as well as transcription 
factors Klf2 and Nr5a2 with a known role in reprogramming, confirming the validity of 
our CRISPRa approach. 
Gene dosage is critical for Oct4 mediated reprogramming 
We observed in our screen that CRISPRa mediated induction of the pluripotency 
marker Oct4 produced a significant number of ESC-like colonies, contradicting 
previous studies which suggest that continuous expression of Oct4 using cDNA is 
inefficient in EpiSC reprogramming11,32. We therefore overexpressed Oct4 via cDNA 
in our EpiSCs and indeed were unable to generate any iPSC colony, while CRISPRa 
achieved robust reprogramming (Figure 2b).  
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We speculated that gene dosage might be the underlying issue and repeated the 
experiment using a tet-inducible Oct4-cDNA with the aim of titrating the Oct4 amount. 
CRISPRa mediated induction of endogenous Oct4 mRNA achieved roughly half the 
expression level found in ESCs, whereas total Oct4 mRNA expression in EpiSCs 
transfected with constitutive Oct4 cDNA slightly surpassed it (Supplementary 
Figure 2c). Titration of Doxycyclin (Dox) mostly resulted in Oct4 mRNA expression 
amounts comparable to constitutive Oct4 cDNA and only very low concentrations of 
Dox gave levels similar to CRISPRa. Nevertheless, all cDNA mediated overexpression 
conditions failed to reprogram EpiSCs, while CRISPRa again succeeded. When 
checking the expression of Oct4 on the protein level via Western Blot, we found that 
Oct4 cDNA derived protein reached disproportionally higher amounts than expected 
from the qPCR results (Supplementary Figure 2d, top panel). CRISPRa, on the other 
hand, achieved Oct4 protein expression similar to that in ESCs (Supplementary Figure 
2d, bottom panel). We suspect that differences in mRNA stability might be the reason 
for these results, as CRISPRa simply drives the endogenous mRNA which then will 
be physiologically regulated, while cDNA derived mRNA could, for example, be more 
stable due to its differing polyadenylation. 
This indicates that CRISPRa could have some additional utility in hitting a goldilocks 
zone of induction for genes where artificially high expression from traditional cDNA 
constructs might prove detrimental. This agrees with our observation that although our 
screening library contained an average of 4 sgRNAs per gene, almost all candidate 
genes from our screen were derived from only one specific sgRNA per target. Indeed, 
when measuring transactivation efficiency of all sgRNAs for the candidate gene Sall1 
and the positive control gene Nanog via qPCR, sgRNAs showed vastly different 
activities in a distribution that suggests a dependency on the distance of the sgRNA 
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to the transcription start site (Supplementary Figure 2e). Indeed, this is also supported 
by a recent report by Liu et al.33 which shows proof-of-principle MEF reprogramming 
using CRISPRa. In their experiments, only sgRNAs targeting the Oct4 promoter in 
very specific locations (-71 and -127 bp from the transcription start site, TSS) achieved 
activation sufficient for reprogramming, while in our experiments, a sgRNA -101 bp 
from the TSS was successful. 
Sall1 facilitates EpiSC reprogramming in cooperation with Nanog 
Umodl1 and Sall1 were the two most potent validated candidates from our screen. We 
confirmed that Umodl1 upregulates Lifr, Essrb, Nanog and Sox2 and downregulated 
Tgfbr1 as would be expected in iPSC reprogramming when media was switched from 
EpiSC to 2i/LIF (Supplementary Figure 2f). We decided to examine Sall1 further 
because, as a member of the Spalt-family of transcription factors, it already had been 
reported to cooperate with Nanog to promote the maintenance of ESC stem cell 
state34,35 and to play an important role in reprogramming and ESC differentiation 
17,19,20,34. However, the downstream targets of Sall1 involved in reprogramming have 
not been sufficiently explored. Having found that Sall1 is also able to independently 
reprogram EpiSCs, we set to investigate the underlying mechanisms. 
First, we asked whether Sall1 and Nanog also act synergistically in EpiSC 
reprograming by overexpressing them individually and combinatorically in Oct4-GFP 
EpiSCs. In order to further validate our experimental approach, we performed these 
experiments both with CRISPRa as well as cDNA mediated overexpression and also 
verified that the observed activity of the Sall1 specific sgRNA was not due to cross-
reactivity with Sall4, a known pluripotency factor (Supplementary Figure 2g). 
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We confirmed CRISPRa induction and cDNA mediated overexpression of Sall1, 
Nanog and Oct4 via RT-qPCR 72h after transfection and found a 2.5 – 3.5 fold 
increase in expression by CRISPRa and a 10 - 20 fold increase in expression through 
cDNA (Supplementary Figure 3a). EpiSC reprogramming efficiencies were evaluated 
as Oct4-GFP+, ESC-like colonies as described above and revealed a marked increase 
in colony number when Sall1 and Nanog were co-expressed (Figure 2a). As 
mentioned above, Oct4 induction via CRISPRa was successful in reprogramming 
EpiSCs in contrast to cDNA overexpression, but we did not observe its significant 
synergy with either Sall1 or Nanog. The reprogrammed colonies exhibited strong GFP 
expression and had an ESC-like morphology (Figure 2b). Pluripotency markers 
examined by RT-qPCR (Rex1, Sox2, Klf4 and Essrb) were markedly increased in all 
the reprogrammed colonies; concordantly, EpiSC markers Gata6, Fgf5 and Otx2 
showed decreased expression (Figure 2c). Sall1 reprogrammed EpiSCs (MF1 and 
C57BL/6 background) contributed significantly to chimeras when injected into 
C57BL/6 blastocysts (Figure 2d and Supplementary Figure 3e). 
In order to exclude the possibility that the baseline GFP expression of the Oct4-GFP 
reporter EpiSCs might skew the correct identification of successfully reprogrammed 
EpiSCs, we repeated these experiments with Nanog-GFP reporter EpiSCs28 which 
show strong GFP expression upon successfully entering the naive ESC state, but 
virtually none in the primed EpiSC state11. Both gene induction using CRISPRa and 
overexpression via cDNA confirmed the reprogramming capability of Sall1 alone and 
in synergy with Nanog (Supplementary Figures 3b-d). Notably, colony formation 
assays in 2i/LIF recapitulated the results obtained with Oct4-GFP EpiSCs and the 
reprogramming kinetics as measured in time course experiments were comparable 
between the two reporter cell lines (Supplementary Figure 3f).  
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Sall1 and Nanog delay differentiation of ESCs into EpiSCs 
ESCs readily differentiate into EpiSCs in culture medium containing the EpiSC self-
renewal factors Activin and FGF2: after 3 passages, the cells begin to acquire the 
characteristics of EpiSCs36. Having confirmed the ability of Sall1 and Nanog to 
reprogram EpiSC, we investigated whether higher levels of Sall1 and Nanog can delay 
this conversion. We generated stable Sall1, Nanog or Sall1+Nanog overexpressing 
Rex1-GFP ESCs37 via PiggyBac mediated transposition of the respective cDNAs. We 
cultured the cells in EpiSC media and used flow cytometry to quantify the Rex1-GFP+ 
population as a measure of cells remaining in the ESC ground state. Nanog and 
Sall1+Nanog transfected cells maintained a significantly higher proportion of GFP+ 
cells across a time course of 21 days (passaged every 2-3 days), whereas Sall1 only 
cells did not (Figure 2e). The expression of naïve pluripotency and EpiSC markers 
analysed by RT-qPCR followed a similar pattern (Supplementary Figures 3g-i), 
although Sall1 only cells delayed upregulating the differentiation markers Fgf5 and 
Otx2. Concordantly, when plated in 2i/LIF medium, Nanog and Sall1+Nanog 
overexpressing cells retained the ability to form ESC colonies through most of the time 
course, and cells overexpressing Sall1 did not show impaired colony formation 
capacity until after 6 days (Figure 2f). This shows that Sall1 does not have the same 
capacity as Nanog to keep the cells at ESC ground state, but may indicate that Sall1 
confers a longer ‘formative state’38 during conversion. 
Sall1 promotes MEF reprogramming and works synergistically with Nanog 
We next tested whether Sall1 can enhance somatic cell reprogramming as well. To 
this end, we stably transfected Oct4-GFP reporter mouse embryonic fibroblasts (Oct4-
GFP-MEFs) with the Yamanaka factors under constant expression via the CAG 
promoter (CAG4F, Supplementary Figure 1) together with dCas9:SAM and Sall1 and 
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Nanog sgRNAs either alone or in combination. Upon allowing them to reprogram in 
ESC media, Sall1 sgRNA transfected MEFs produced a significantly higher number of 
Oct4-GFP+ and Alkaline Phosphatase positive (AP+) colonies (Figure 3a and 
Supplementary Figure 4a) with ESC-like morphology (Supplementary Figure 4b) 
compared to CAG4F alone, mirroring the results obtained from EpiSC reprogramming, 
including synergism between Sall1 and Nanog.  
In order to examine the dynamics of MEF reprogramming, we chose cDNA mediated 
tetracycline-inducible Sall1 expression (TRESall1, Supplementary Figure 1 and 
Supplementary Table 2). Initially, we co-transfected Oct4-GFP-MEFs with TRESall1 
and CAG4F. We cultured the transfected cells in ESC medium (M15) and induced 
Sall1 expression with three different concentrations of Doxycycline (Dox, 0.1, 0.5 and 
1.0 µg/ml) to find a suitable concentration to mediate reprogramming. After 18 days in 
culture, Oct4-GFP+ colonies were counted and stained for AP to identify iPSC 
colonies. Doxycycline concentrations of 0.5 or 1.0 µg/ml resulted in a significant 2 to 3-
fold increase in Oct4-GFP+ and AP+ colonies (Figure 3b and Supplementary Figure 4c) 
and we chose a Doxycycline concentration of 0.5 µg/ml for all subsequent 
experiments. To determine whether there is a time point during reprogramming 
beyond which Sall1 will not improve the efficiency any further, we again co-transfected 
MEFs with CAG4F and TRESall1 and induced Sall1 expression at 0, 2, 4, 6, 8, 10 and 
12 days of reprogramming. As before, we counted Oct4-GFP+ and AP+ colonies after 
18 days and observed that only Sall1 expression during the first four days resulted in 
higher reprogramming efficiency, whereas Sall1 induction at a later stage did not 




Nanog has been reported to promote MEF reprogramming39 and in order to elucidate 
whether - similar to the effect on EpiSC reprogramming - Sall1 can act synergistically 
here as well, we co-transfected MEFs with combinations of inducible expression 
vectors for the Yamanaka factors, Nanog and Sall1 (TRE4F, TRENanog and 
TRESall1). We induced expression as before and counted reprogrammed colonies at 
day 18 according to Oct4-GFP+ fluorescence and AP+ staining. We observed that co-
expression of Sall1+Nanog/4F led to a 1.5-fold increase in colony number over 
expression of either Sall1/4F or Nanog/4F (Figure 3a and Supplementary Figure 4a), 
indicating synergism between the two factors in MEF-reprogramming. 
The Sall1-iPSCs derived from these experiments were morphologically similar to 
ESCs with a compact dome like structure and expressed the Oct4-GFP reporter. 
Moreover, immunofluorescent staining of these iPSCs showed protein expression of 
the ESC-markers SSEA-1 and Nanog (Figure 3c). When we cultured these iPSCs in 
differentiation medium (DMEM/10% FCS or N2B27 medium40), the colonies exited 
ground state pluripotency and differentiated into mesoderm, endoderm and ectoderm 
lineages as confirmed by immunofluorescent staining for expression of smooth muscle 
actin (SMA), alpha fetoprotein (AFP) and β-Tubulin III (Figure 3d). In addition, when 
we injected these iPSCs into blastocyst, live chimeras were born (Figure 3e). Both in 
vitro and in vivo data confirmed the pluripotency of these Sall1-iPSCs. 
Female mESCs have two activated X chromosomes when maintained at ground 
state41 and randomly inactivate one of them once they undergo differentiation. Staining 
with anti- H3K27me3 antibody detects this event as foci on the inactivated X 
chromosome42. We derived iPSCs from female MEFs by co-transfecting with 4F/Sall1 
as before and then differentiated them in DMEM/10% FCS for 5 days. Loss of Oct4 
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expression demonstrated successful differentiation and the presence of H3K27me3 
foci indicated X chromosome silencing. In contrast iPSC cultured in 2i/LIF strongly 
expressed Oct4 protein and lacked any H3K27me3 foci (Figure 3f). Together, this data 
demonstrates that Sall1 can enhance 4F driven somatic cell reprogramming and that 
4F/ Sall1 reprogrammed iPSCs are naïve and pluripotent. 
It was previously reported that only three Yamanaka factors (Oct4, Sox2 and Klf4) are 
essential and sufficient for reprogramming, albeit at a lower efficiency than in 
conjunction with c-Myc. Moreover, the three essential factors can be replaced by other 
transcription factors or small molecules such as Gata343 or valproic acid44-46. We co-
transfected MEFs with tet-inducible Sall1 and three different expression constructs, 
each containing c-Myc and two out of three essential factors (Klf4 and Sox2, CKS; 
Oct4 and Klf4, OCK; Oct4 and Sox2, OCS). After 18 days of culture in Doxycycline-
containing 2i/LIF medium, we could not observe iPSC colonies in any of the 
combinations (Supplementary Figures 4e-g), indicating that Sall1 cannot replace the 
function of either Oct4, Sox2 or Klf4 in MEF reprogramming. 
RNA-seq identifies potential mechanisms of cellular reprogramming mediated 
by Sall1 and Nanog 
In order to find downstream targets of Sall1 and Nanog, we transfected Oct4-GFP 
EpiSCs with cDNA for either gene alone or in combination as described above and 
performed RNA-seq after 24 h of overexpression. Our analysis identified 372 genes 
that were differentially expressed specific to Sall1 transfected cells compared to empty 
vector, and 307 genes specific to Nanog transfected cells. We observed a large 
overlap of 568 genes (45%) between both sets (Figure 4a, Supplementary Table 8) 
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and GOTERM analysis revealed that they are involved in a number of developmental 
processes and signalling cascades (Figure 4b, Supplementary Table 8). 
Amongst those commonly regulated genes were Myc, Mycn, Tet3, Tex10, Jarid2, 
Fgfr1, Mbd2, Lifr and Smad7 (Figure 4a) which have previously been implicated in the 
promotion of cellular reprogramming or inhibition of ESC differentiation 8,47-56. 
Upregulation of the Lif receptor (Lifr) and downregulation of the Fibroblast Growth 
Factor Receptor (Fgfr1) is expected in EpiSC reprogramming and validates our RNA-
seq and RT-qPCR data (Figure 4c). Furthermore, we found 215 genes which were 
only regulated when Sall1 and Nanog were overexpressed together (Supplementary 
Figure 4h and Supplementary Table 8), such as Dnmt3c and Hdac9, reported to be 
involved in the epigenetic regulation of male germ cell maintenance57 and muscle 
differentiation58,59, respectively; as well as a modest upregulation of Utf1, a 
transcription factor known to synergize with the Yamanaka factors in reprogramming60. 
We had already independently identified the genes Klf5 and Fam189a2 in our GoF 
screen (Figure 1e, Supplementary Table 5) and RNA-seq showed them to be 
potentially regulated by Sall1 and Nanog, respectively. We validated the RNA-seq 
results for these genes with RT-qPCR in EpiSCs 24 h after cDNA transfections 
(Sall1/Nanog/Sall1+Nanog) and found a good correlation between both methods 
(Figure 4c). While Klf5 narrowly failed the stringent P value cut-off for the RNA-seq 
results in Nanog overexpressing cells, RT-qPCR indicated that Klf5 may be regulated 
by Nanog as well, albeit to a lesser extent than by Sall1. Fam189a2 on the other hand 
seemed to be regulated significantly stronger by Nanog than Sall1. When we co-
expressed Sall1 and Nanog, we did not observe a significant increase in expression 
for these downstream targets compared to Sall1 or Nanog alone (Figure 4c); we did 
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however find synergistic elevation of expression for the genes Myc, Mycn61 and Arid2, 
all of which have been shown to play a role in reprogramming and chromatin 
remodelling 62,63.  
We used CRISPRa to induce expression of Klf5, Fam189a2, Tex10 and Tet3 in Oct4-
GFP EpiSC and found that all were able to augment reprogramming into iPSCs 
(Figure 4d). Reprogramming by Fam189a2 occurred in 10 days, while Klf5, Tex10 and 
Tet3 required between 14 and 20 days. In all cases, the number of reprogrammed 
colonies was significantly lower than compared to Sall1 or Nanog (Figure 4g), which 
may indicate that multiple downstream targets of Sall1 and Nanog participate in 
reprogramming.  
We tested the regulatory relationship between Sall1+Nanog and Klf5+Fam189a2 by 
transfecting EpiSCs with CRISPRa for Klf5 and Fam189a2. CRISPRa significantly 
increased Klf5 and Fam189a2 transcription, respectively, but not Sall1 and Nanog 
expression, indicating Klf5 and Fam189a2 are respective downstream targets of Sall1 
and Nanog (Figure 4e). We then investigated some of the key genes which were 
differentially expressed in RNA-seq data. After culturing transfected EpiSCs in EpiSC 
medium, the cells were collected for RT-qPCR analysis. We observed that both Sall1 
and Klf5 up-regulated Smad7 (negative regulator of TGF-β signalling and activator of 
Stat364), Gp130 and Lifr, suggesting the repression of TGF-β signalling and activation 
of Jak/Stat3 signalling. Nanog and Fam189a2 on the other hand down-regulated 
Fgfr1, Tgfr1 and Mbd2 and up-regulated Esrrb expression, indicating the repression 
of FGF and TGF-β signalling, inhibition of epigenetic repression and promotion of self-
renewal and pluripotency (Figure 4f). Functionally, co-activation of both Klf5 and 
Fam189a2 generated significantly more Oct4-GFP+ colonies than Klf5 or Fam189a2 
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alone. As expected, co-activation of either Sall1 and its downstream target Klf5 or 
Nanog and its downstream target Fam189a2 showed no synergistic effects in Oct4-
GFP+ colony production, whereas co-activation of either Sall1 and Fam189a2 or 
Nanog and Klf5 resulted in increased numbers of Oct4-GFP+ colonies compared to 
Klf5 and Fam189a2 co-activation (but lower than Sall1 and Nanog co-activation). 
Collectively these results suggest that Klf5 and Fam189a2 are situated downstream 
of Sall1 and Nanog, respectively, and can synergise similar to Sall1 and Nanog albeit 
with a lower efficiency than their upstream regulators (Figure 4g). 
Discussion 
With the advent of CRISPR/Cas9, genomic in vitro screening has become sufficiently 
accessible and affordable to enable experiments at a genome wide scale and is 
typically used in the context of loss of function by exploiting the ability of wildtype Cas9 
to induce double strand breaks in the target DNA. Catalytically dead Cas9 fused to 
transcriptional activator proteins on the other hand opens up the possibility of driving 
gene expression. To date few CRISPR activation screens have been performed65-67 
using previously established gain-of-function libraries21,68,69. However, none of them 
targeted stem cell reprogramming and while some recent publications have used 
CRISPRa in this field of research, they have been restricted to a few genes to 
demonstrate proof-of-concept33,70,71. 
Our present study shows that a genome-scale CRISPRa screen, in conjunction with 
an experimental model such as epiblast stem cells in which a single overexpressed 
gene may mediate reprogramming to pluripotency, is a powerful tool for gene 
discovery. We identified 142 candidate reprogramming factors and found amongst 
them known pluripotency factors such as Nanog and Oct4, principally validating our 
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approach. Nanog overexpression can reprogram EpiSCs to iPSCs and deletion of 
Nanog almost completely impairs reprogramming in somatic cells (unless ascorbic 
acid is supplied in the ESC medium)72-74. Oct4 is one of the Yamanaka factors in 
somatic reprogramming3 and the level of Oct4 seems critical for maintenance of ESCs 
and differentiation75, as it has been reported that an artificially reduced level of Oct4 
maintains ESCs in a robust pluripotent state, whereas wild-type levels of Oct4 enable 
differentiation76,77. Curiously, while in our current work CRISPRa induced Oct4 readily 
and robustly reprogrammed EpiSCs into iPSCs, overexpression via cDNA in the past 
has failed to do so11, a result we were able to reproduce here. We show that gene 
dosage is one critical aspect to explain this behaviour and it is conceivable that too 
high a level of Oct4, especially when supplied exogenously, is detrimental to 
pluripotency78,79. This has important implications for screening approaches similar to 
ours: while traditional systems like cDNA libraries only produce a singular expression 
level per gene, we and others33 show that CRISPRa in conjunction with sgRNAs tiled 
throughout the regulatory regions of genes can provide a multitude of expression 
levels and thus a higher probability of matching the physiological gene dosage. This 
gives CRISPRa mediated approaches much more flexibility, to the point where 
smaller, targeted screens with many sgRNAs per gene may be used to probe the 
regulatory regions of genes of interest. 
Along similar lines, the choice of CRISPRa system may well influence the outcome of 
a screen: We tested several systems and chose SAM for our screen as it achieved the 
highest expression levels and it is conceivable that repeating our screen with a 
different CRISPRa system at lower activation efficiencies could produce a non-
redundant list of candidate genes. 
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The observation that sgRNA activities vary depending on their position with respect to 
the TSS certainly serves to explain why most of our candidate genes were only 
identified by a single sgRNA in our screen. However, we also acknowledge that 
reprogramming is inherently a very inefficient process and thus, a very large initial cell 
number may be required to deeply cover a genome-wide library and give a sufficient 
number of cells a chance to gain pluripotency. While we performed our GoF screen 
with 10 x 106 library-transduced cells (library coverage 114x), a deeper coverage or a 
more focused library promises to uncover reprogramming candidates the present 
screen might have missed. 
Our screen identified Sall1 as a potent EpiSC reprogramming factor. Sall1 is a member 
of the Spalt-like gene family which in mice comprises 4 genes – Sall1, 2, 3 and 4. Sall1 
and Sall4 have been implicated in the establishment of pluripotency18 in studies 
showing that the action of demethylase Utx on Sall1 and Sall4 is required to enable 
MEF reprogramming17. Furthermore, it has been demonstrated that Sall4 activates 
Oct4 expression while Sall1 is a direct binding partner of Nanog34,80 and has been 
suggested to be required in Nanog-mediated open heterochromatin maintenance 
within ESCs and EpiSCs35. So far, it is unclear whether Sall1 plays an active role in 
EpiSC reprogramming. In our work, we demonstrate that by either activation of 
endogenous Sall1 expression via CRISPRa or by overexpression of transgenic Sall1, 
EpiSCs can be reprogrammed to iPSCs. We show by combined overexpression that 
Sall1 and Nanog synergistically augment reprogramming of EpiSCs and MEFs. 
However, Sall1 cannot replace Oct4, Sox2 or Klf4 in MEF reprogramming, suggesting 
that unlike these core pluripotency factors, Sall1 alone cannot initiate the 
reprogramming machinery in more differentiated cells. It can be postulated that one of 
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its roles may be in facilitating epigenetic modification and nucleosome remodelling e.g. 
through interaction with Nanog and the deacetylase complex (NurD)20,81. 
The ability of Sall1 to reprogram EpiSCs, however, is not sufficient to keep ESCs in 
the naive pluripotent state. Unlike Nanog, overexpressing Sall1 in ESCs only 
marginally delayed loss of pluripotency in differentiation experiments. However, it 
slowed expression of EpiSC markers Fgf5 and Otx2 and preserved the ability to 
generate ESC-like colonies. In embryoid body differentiation of ESCs, overexpression 
of Sall1 inhibited Otx2 expression and a formative pluripotent phase between naïve 
and primed states was postulated when cells lost naïve pluripotency markers and 
gained post-implantation markers such as Otx2 and Oct6 among others34,38. 
Considering that even after 21 days in differentiation medium, some Sall1 
overexpressing cells still formed ESC like colonies in 2i/LIF, these cells may be stalled 
in a formative state. 
We used RNA-seq to identify downstream targets of Sall1 and Nanog in EpiSCs and 
found novel genes as well as factors previously implicated in pluripotency or stem cell 
maintenance. Esrrb, a downstream target of Nanog, plays an important role in 
maintaining ESCs pluripotency and reprogramming by interacting with the core 
pluripotency network via Sox282,83. Tex10 was recently reported to be a pluripotency 
factor and partner of Sox2, capable of promoting MEF reprogramming84, a role we 
further extended to EpiSC reprogramming. Tet3 is a member of the ten-eleven 
translocation (Tet) protein family, which regulate DNA methylation. Tet1 and Tet2 have 
already been implicated in somatic reprogramming and Tet2 has been reported to 
promote EpiSCs to a naïve state51,53. Here, we show that Tet3 can mediate EpiSC 
reprogramming as well. 
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The Krueppel-like factor family proteins Klf2, 4, 5 are also pluripotency factors and 
both Klf2 and Klf4 have been shown to facilitate reprogramming. The potential of Klf5 
however is unclear as it has been reported to be incapable of reprogramming EpiSCs 
in a study by Hall et al.85, while Jeon et al. and recently Azami et al., both were able to 
derive iPSCs from EpiSCs by cDNA mediated Klf5 overexpression86,87.  
Our RNA-seq analyses demonstrated synergistic pathways through which Sall1 may 
function together with Nanog in increasing reprogramming efficiency. We identified 
Klf5 in our GoF screen and confirmed its ability to reprogram EpiSCs via CRISPRa 
transcriptional activation. RT-qPCR validation also suggested that Klf5 is one of the 
downstream targets of Sall1. Similar to our observations with Oct4, this may reflect a 
Goldilocks effect of gene expression levels and highlights the utility of different 
overexpression approaches to discover new pluripotency factors. LIF dependent 
activation of Jak/Stat3 and its role in ESC self-renewal and reprogramming has been 
widely studied to date64,88. cDNA overexpression of Klf5 has been shown to 
compensate for the absence of LIF in maintaining pluripotency of ESCs and that it can 
also reprogram EpiSC via LIF-independent pathways86,89. Besides Klf5, our data also 
indicates that Sall1 positively and negatively regulates the Jak/Stat3 and TGFβ 
pathways by upregulating the Gp130, Lif receptor and Smad7 respectively, together 
providing a novel role of Sall1 in EpiSC reprogramming. 
Fam189a2 was identified as a new target of Nanog in EpiSC reprogramming and our 
data showed that both Nanog and Fam189a2 downregulate the Tgfbr1 and upregulate 
Esrrb expression. We postulate that the observed synergy between Sall1 and Nanog 
as well as their downstream effectors Klf5 and Fam189a2 is partially due to the 
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combined activation of Jak/Stat3, suppression of TGFβ signalling and upregulation of 
pluripotent genes such as Esrrb. 
In conclusion, using a genome-scale CRISPR activation screen in the well-established 
EpiSCs reprogramming model, we identify known and previously unknown genes that 
can mediate cellular reprogramming in EpiSC. We demonstrate that the transcription 
factor Sall1 can effectively reprogram EpiSC and MEFs and provide new insights into 
the role of Sall1 in promoting and maintaining pluripotency. Other novel 
reprogramming candidates such as transcription factors Atf1 and Bhlha15, kinases 
Idnk and Has1, several olfactory receptor genes (Olfr) and others with less known 
functions like Umodl1 and Prr3 deserve further in-depth investigation. Our studies 
demonstrate the strengths of CRISPRa screens in the identification of novel factors in 






All animal experimental procedures were carried out in accordance with Home Office 
UK regulations and the Animals (Scientific Procedures) Act 1986 (licence No. 70/8387 
and 80/2552). All experimental protocols were approved by the Animal Welfare and 
Ethical Review Body (AWERB) of Wellcome Genome Campus and the University of 
Cambridge CRUK Cambridge Institute. At the end of the study, mice were euthanized 
in accordance with stated Home Office UK regulations. 
Constructs 
Guide RNAs (sgRNAs) were expressed under the U6 promoter in expression 
constructs (pKLV-PB-U6-gRNA-PGK-Puro-T2A-TagBFP, Supplementary Figure 1) 
harbouring PiggyBac inverted terminal repeats to enable transposase-mediated 
genomic integration (PB transposon) and HIV-1 long terminal repeats to allow lentiviral 
genomic integration (Supplementary Figure 1). The sgRNA scaffold used in 
conjunction with dCas9:SAM was adapted to contain two MS2-binding loops as 
required by the SAM CRISPRa system69. The constructs also included a puromycin 
antibiotic resistance and a TagBFP marker. The four dCas9 variants were cloned into 
PB transposons and included the mCherry fluorescent marker and Blasticidine 
antibiotic resistance. The dCas9 cDNAs in these constructs were driven by the Ef1-α 
promoter and multiple consecutive cDNAs were linked by the T2A self-separating 
peptide sequence. 
cDNAs of Oct4, c-Myc, Klf4, Sox2, Sall1 and Nanog were cloned into PiggyBac 
transposons under the control of the CAG promoter (PBCAG) or the Tet response 
element (PBTRE). Combinations of cDNAs were linked by the T2A self-separating 
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peptide sequence. PBEF1α-TET3G encoding the Tet-On-3G transactivator protein 
was co-transfected with PBTRE-cDNA to enable Doxycycline induction of the PBTRE 
constructs.  
When stable integration by transposition of the transgene was required, a plasmid 
encoding PiggyBac transposase (HyPBase90) was co-transfected. Schematic 
representations of all the constructs used in the study are shown in Supplementary 
Figure 1. 
Cell Culture 
Oct4-GFP and Nanog-GFP Epiblast stem cells (EpiSCs) were generated as described 
previously28. Briefly, EpiSC were derived from post-implanted pregnant transgenic 
mice at E5.75. Cells from embryos were cultured on human fibronectin (Millipore) 
coated plates in complete EpiSC media based on N2B27 which comprised 50% 
Neurobasal media, 50% DMEM-F12 media, 0.1mM -ME, penicillin (100 U/ml), 
streptomycin (100 µg/ml), L-glutamine (2 mM), 1X N2 and 1X B27 supplement 
(Invitrogen) and was supplemented with 20 ng/ml Activin-A (R  & D Systems) and 
12 ng/ml FGF2 (Peprotech). When confluent, the media was aspirated and the EpiSC 
were dissociated with Accutase (Millipore) for 3 min. Dissociated cells were spun down 
at 300g for 5 min and plated either at 1:6 or at 1:8 split ratio on human fibronectin 
coated plates in complete EpiSC media for maintenance.  
For screening and reprogramming, EpiSCs were cultured in 2i/LIF medium comprising 
N2B27 media (as above) supplemented with 100 U/ml leukemia inhibitory factor (LIF, 
Millipore), 1 µM PD0325901 (Tocris) and 3 µM CHIR99021 (Tocris). 
Rex1-GFP embryonic stem cells (ESCs) cells were generated as described 
previously37. ESCs were cultured on 0.1% gelatin coated plates. ES cells were 
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regularly maintained in ESC medium (M15) comprising knock-out DMEM containing 
15% FBS, 0.1mM -ME, penicillin (100 U/ml), streptomycin (100 µg/ml), L-glutamine 
(2 mM), and 100 U/ml LIF. Confluent ES cells were dissociated with 0.025% Trypsin-
EDTA for 5 min. Detached cells were collected and spun down at 300g for 5 min and 
were plated at a split ratio of either 1:8 or at 1:10 on gelatin coated plates. 
Mouse embryonic fibroblasts (MEFs) were cultured in M10 medium comprising knock-
out DMEM containing 10% FBS, 0.1mM -ME, penicillin (100 U/ml), streptomycin 
(100 µg/ml) and L-glutamine (2 mM). For reprogramming, after transfection, cells were 
cultured in ESC medium until the end of experiment or until the colonies were picked 
for iPSC line derivation. 
GoF gRNA library design 
The Gain of Function (GoF) library targeted the region of up to 250 base pairs 
upstream of the transcription start site (TSS) of each protein-coding gene. Up to 4 
guides of 19 bp length were selected per gene. Protein coding genes and TSSs were 
obtained from the mouse reference assembly GRCm38 in the ENSEMBL database 
(version 78, http://www.ensembl.org,)91 and TSSs were checked against CAGE data 
in the FANTOM data base (April 2015, http://fantom.gsc.riken.jp/)92. 
Potential guide sequences were identified on the reference assembly as the 19 bp 
sequence at the 5' end of each PAM motif (NGG), i.e. 2 to 20 bp upstream of each 
guanosine di-nucleotide in the reference. Guide sequences consisted of no more than 
13 guanosine or cytosine bases (GC content < 70%). Guides in the 250 bp region on 
both DNA strands upstream of the TSS were then compared to all other potential guide 
sequences across the genome. Guide sequences with off-target sites exhibiting fewer 
than 3 mismatches over their 19 bp length were omitted from the design. 
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The remaining guides were sorted by a simple ad-hoc quality score intended to reflect 
a likely increased tolerance of mismatches distal of the PAM motif. For each potential 
off-target site a score was calculated that linearly increased with the number of 
mismatches and decreased with their distance to the PAM motif.  
A selection algorithm was designed to spread high quality guides across the target 
region. To this end, the region upstream of the TSS was divided in quarters of roughly 
equal length. Starting with the quarter closest to the TSS the algorithm looped over 
quarters picking the best guide, by quality score, in each if available and adding it to 
the library until no more guide fitting the constraints could be found, or the target 
number of 5 guides per genes was reached. A constraint for the GC content of less 
than 55% was applied in the first loop and then relaxed to 70%. 
GoF reprogramming screen 
The GoF sgRNA library was synthesized by Custom Array, and the oligo pools were 
cloned into the lentiviral sgRNA expression plasmid via Gibson assembly as described 
by Shalem et al.93, with minor modifications. 
Oct4-GFP EpiSC cells were transfected with 200 ng of plasmid encoding PiggyBac 
transposase together with 1 µg dCas9:SAM to facilitate stable integration. 
Transfections were performed with Lipofectamine LTX (Invitrogen), according to 
manufacturer’s instructions. Transfected cells were then selected by 10 µg/ml 
Blasticidine (Gibco) for 10 days. Post-selection, dCas9:SAM expressing Oct4-GFP 
EpiSC were expanded to 100 x 106 cells for lentiviral transduction. 
Library transduction was carried out at a MOI (multiplicity of infection) of 0.3. After two 
days, 10 x 106 BFP+ Oct4-GFP EpiSCs were sorted by flow cytometry. The sorted 
cells were seeded on fibronectin coated plates and allowed to recover in complete 
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EpiSC medium for 24 h. The medium was then changed to 2i/LIF in order to allow 
selection for reprogrammed cells. After 14-16 days in 2i/LIF, the individual 
reprogrammed colonies, verified by Oct4-GFP fluorescence, were picked and 
transferred to 96 well plates. Colonies were passaged twice in 2i/LIF before 
sequencing. Genomic DNA was extracted from each colony and PCR amplification 
across the stably integrated sgRNA was performed using primers described 
previously94. PCR amplicon libraries were pooled and Next Generation Sequencing 
was used to identify the distribution of sgRNA sequences.  
CRISPRa transfections 
Oct4-GFP EpiSC and Nanog-GFP EpiSC cells were grown to 70% confluence on 
fibronectin coated 6-well plates. The cells were dissociated with Accutase and re-
suspended in EpiSC media for reverse transfections (approx. 1 X 106 cells in 250 µl 
per transfection). 
Cells were transfected with 500 ng PiggyBac transposase together with 500 ng 
dCas9:SAM and 500 ng of sgRNA expression construct for one or more sgRNAs. 
Transfections were performed using Lipofectamine LTX (Invitrogen), according to 
manufacturer’s instructions. Cells were cultured in EpiSC medium for 24 h. Stably-
transfected cell lines were generated by selection with Blasticidine (10 µg/ml) for at 
least 10 days post-transfection. Integration of constructs was confirmed by PCR 
genotyping (Supplementary Table 1). 
cDNA transfections 
Oct4-GFP EpiSCs, Nanog-GFP EpiSCs and Rex1-GFP ESCs were transfected with 
1 µg PBCAG expressing either Sall1, Nanog or a combination of both vectors via 
Lipofectamine LTX. Cells were co-transfected with plasmids encoding PiggyBac 
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transposase (500 ng) and mCherry Blasticidine (100 ng) selection markers to enable 
selection of transfected cells. Presence of PBCAG in the selected cells was confirmed 
with PCR (Supplementary Table 1). 
EpiSC Reprogramming 
Stable lines of Oct4-GFP and Nanog-GFP EpiSC generated either from CRISPRa or 
cDNA transfections were plated in triplicate on fibronectin coated 6-well plates in 
EpiSC medium. Medium was changed to 2i/LIF when cells reached 80% confluence 
and thereafter replaced every 2 days to select for reprogramming for up to 20 and 
24 days for Oct4-GFP transfected EpiSCs and Nanog-GFP transfected EpiSCs, 
respectively. GFP+ ESC-like colonies were counted and transferred onto gelatin 
coated plates for expansion. Expanded colonies were then phenotyped for gene 
expression by RT-qPCR (Supplementary Table 3). 
To derive iPSCs for blastocyst injection, Oct4-GFP EpiSC were transfected with 1 µg 
PBTRESall1, 1 µg PBTET3G and 2 µg transposase using Lipofectamine LTX. 
Transgene expression was induced by supplementing the medium with 0.5 µg/ml 
Doxycycline after switching the cells to 2i/LIF. 
Flow cytometry analysis of EpiSC reprogramming 
Stably transfected CRISPRa Oct4-GFP and CRISPRa Nanog-GFP EpiSC were plated 
in triplicates on fibronectin coated 24-well plates at a density of 50,000 cells per well, 
in EpiSC media. Upon reaching confluence, the media was changed to 2i/LIF to select 
for reprogramming. Cells were harvested at regular time intervals and were analysed 





For sgRNA mediated reprogramming of MEFs, 1 x 106 Oct4-GFP MEFs were 
electroporated with 0.5 µg PBCAG4F, 1 µg gRNA Sall1 / 1 µg gRNA Nanog / 0.5 µg 
gRNA Sall1+0.5 µg gRNA Nanog, 1 µg dCas9:SAM and 0.5 µg PiggyBac transposase 
using the Amaxa Nucleofector (Amaxa, Lonza). The transfected cells were plated onto 
gelatin-coated 10 cm dishes in M15. After 24 h, the medium was replaced and was 
renewed every two days until day 18 when Oct4-GFP+ and AP+ cells were counted.  
For inducible cDNA mediated reprogramming, 1 x 106 Oct4-GFP MEFs were 
electroporated with 1 µg PBTRE4F, 0.5 µg PBTRESall1, 2 µg PBEF-1αTet3G and 
2 µg PiggyBac transposase using the Amaxa Nucleofector (Amaxa, Lonza). The 
transfected cells were plated in gelatin-coated 10 cm dishes in ESC medium. After 
24 h, the medium was replaced and three different concentrations of Doxycycline (0.1, 
0.5 and 1.0 µg/ml) were tested for induction of cDNA expression. At day 12, 
Doxycycline was withdrawn and the cells were cultured for 6 more days, after which 
Oct4-GFP+ and alkaline phosphatase stained colonies were counted and single 
colonies picked for RT-qPCR. 
To produce iPSCs for in vitro and in vivo assays, C57B/6J MEFs were transfected with 
the same amount of PBTRE4F, PBTRESall1, PBEF1α-TET3G and PiggyBac 
transposase as described above and induced with 0.5 µg/ml Doxycycline in ESC 
media. 
All the combinations of cDNA transfections for MEF reprogramming are listed in 
Supplementary Table 2. 
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Western Blotting  
Oct4-GFP EpiSCs transfected with CRISPRa Oct4 and cDNA Oct4 (both CAG and 
TRE) together with experimental controls and untransfected cells (EpiSCs and ESCs) 
were collected for Western blotting after 3 days 2i/LIF (Dox induction for 3 days). 
Protein amounts were determined using a Bradford assay and 30 µg of lysates were 
subjected to electrophoresis on 4–15% Mini-PROTEAN® TGX™ Precast Protein Gels 
(Biorad). Proteins were transferred onto PVDF membranes (Millipore) overnight at 
30 V for 8 hours at 4C. Transferred proteins were then immunoblotted for Oct4 (c-10, 
Santa Cruz, #sc-5279, dilution 1:800) and Gapdh (Sigma, #G8795, dilution 1:4000). 
All antibodies used are listed in Supplementary Table 4. 
Conversion of ESCs to EpiSCs 
Stable lines of cDNA transfected Rex1-GFP ESCs were cultured in 2i/LIF medium for 
3 days prior to the conversion. Upon reaching 50% confluence, cells were dissociated 
and seeded on gelatin-coated plates in EpiSC medium for conversion for at least 
3 passages. Cells were seeded on fibronectin-coated plates after the 2nd passage to 
promote differentiation. In addition, 600 cells were plated back on 0.1% gelatin coated 
plates in 2i/LIF medium for about 7 days to promote formation of iPS colonies. The 
colonies were assessed by AP staining. Lastly, at every passage, cells were assessed 
for Rex1-GFP fluorescence using flow cytometry and total RNA was extracted for RT-
qPCR. 
Quantitative RT-PCR (RT-qPCR) 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) according to 
manufacturer’s instructions. First strand cDNA was synthesized using qScript cDNA 
Supermix (Quantabio) according to manufacturer’s protocol. All qPCR studies were 
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performed using Taqman Gene Expression Assays either in the 7900HT Fast Real-
Time PCR system (Applied Biosystems) or the StepOnePlus™ Real-Time PCR 
System (Applied Biosystems). Samples were run in triplicate for both gene of interest 
and house-keeping genes. Expression levels were normalized to Gapdh. TaqMan 
probes used are listed in Supplementary Table 3. 
RNA-sequencing 
Oct4-GFP EpiSCs were transfected via Lipofectamine LTX with 1 µg PBCAGSall1, 
PBCAGNanog, PBCAGSall1+PBCAGNanog or empty vector (PBCAG:Empty). Cells 
were co-transfected with CAGmCherry (100 ng) to enable fluorescent marker 
selection. All transfections were performed in triplicates. 24 h later, cells were FACS 
sorted for GFP+mCherry+ and their RNA was extracted using the Rneasy Mini Kit 
(Qiagen) according to manufacturer’s instructions. Illumina Truseq NGS libraries were 
prepared and sequenced on a Illumina HiSeq instrument. 
Sequencing results were analysed by aligning reads to the mouse genome build 
GRCm38.p5 using the STAR aligner (Ver. 2.5.3a) and read counts were prepared with 
the TOPHAT package. Differential expression of genes was analysed with the 
DESeq2 package for the R statistical computing framework. We used a cut-off padj 
value of <0.001 to determine genes that were differentially regulated between 
experimental and control samples. 
GO Term analysis 
We used the GoToolBox platform (http://genome.crg.es/GOToolBox/) to perform 
enrichment analysis on the genes identified in the CRISPRa screen and via RNAseq 
as described previously95. In brief, a Data-Set was created using the Mouse Genome 
Informatics version (MGI) and then used for pathway enrichment analysis. Fold 
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changes for enriched gene sets were computed by dividing the frequency in our set 
by that of the reference. Representative pathways with a fold change of 2 or more and 
with a p-value of 0.05 or lower were graphically represented in the results.  
Immunofluorescence 
C57BL/6J MEF reprogrammed iPSCs were plated at 2 x 103 onto 24 well plates in 
2i/LIF. After 24 hours, cells were washed with PBS and fixed in 4% paraformaldehyde 
(PFA), blocked and permeabilised with 1% bovine serum albumin (BSA) and 3% 
serum in PBS with 0.1%Triton X100. Samples were incubated with mouse anti-SSEA-
1 (BD Biosciences) or rabbit anti-Nanog (Abcam) antibodies at 4℃ overnight, then 
rinsed and incubated with Alexa488-conjugated goat anti-Mouse IgM and Alexa594-
conjugated goat anti-Rabbit IgG (Invitrogen), and counterstained with DAPI.  
To examine the X chromosome status in female iPSCs, cells were plated at 5 x 103 on 
gelatin coated slides in 2i/LIF or in M10 medium for 5 days, then cells were fixed in 
4% PFA, and immunofluorescence was performed as mentioned above. Slides were 
incubated with rabbit anti-H3K27me3 (Millipore) and mouse anti-Oct4 antibodies 
(Santa Cruz), then Alexa594-conjugated goat anti-Rabbit IgG and Alexa488 goat anti-
Mouse IgG and counterstained with DAPI. All antibodies used are listed in 
Supplementary Table 4. 
In Vitro differentiation 
C57BL/6J MEF reprogrammed iPSCs were plated at 5 x 105 in a petri-dish in M10 
medium for 4 days, then dissociated with 0.05% Trypsin/EDTA and plated at 1 x 105 
in M10 on gelatinized plates for another 4 days. The cells were then fixed in 4% PFA 
and examined for mesoderm and endoderm markers using immunofluorescent 
staining with antibodies against smooth muscle antigen (SMA) (R&D Systems) and 
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alpha fetoprotein (AFP) (R&D Systems). For neuronal differentiation, cells were plated 
at 1.5 x 105 in N2B27 medium on gelatinized plates. The medium was changed every 
other day and at day 8, the cells were fixed and stained with anti-beta tubulin III (Tuj1) 
antibody (R&D Systems). 
Chimeras 
Chimeras were produced by a standard microinjection protocol. Chimerism was 
estimated based on coat colour since iPSCs derived from EpiSCs and MEFs are of 
MF1 and C57BL/6J genetic background (agouti and black furs) whereas the host 
blastocysts were from albino C57BL/6. 
Statistical analyses 
All statistical analyses were performed in GraphPad Prism (Version 6.01). Data are 
presented as means ± standard deviations. Statistical significance was determined 
either using a Student’s unpaired t-test with two-tailed distribution or Two-way ANOVA. 
Students’ t-test was used for comparison across two groups while Two-way ANOVA 
with multiple comparisons were performed on samples undergoing a time course 
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Figure 1 | GoF EpiSC reprogramming screening with CRISPRa and sgRNA 
library 
(a) Activation of Ascl1 and Neurog2 in HEK293 cells. Cells were transfected with one 
sgRNA per target and four different dCas9 versions. Gene expression was analysed 
by RT-qPCR and compared to GAPDH expression, fold change is expressed relative 
to dCas9:VP160 for each gene (* p<0.05; *** p<0.001). (b) Illustration of sgRNA 
design targeting gene promoters in the murine genome. (c) Screening strategy using 
Oct4-GFP EpiSCs with stable expression of dCas9:SAM and lentiviral transduction 
(MOI 0.3) of the sgRNA library. Reprogramming took place in 2i/LIF for 14-16 days, 
after sorting for transduced cells. Oct4-GFP+ iPSC colonies were then picked and NGS 
identified candidate sgRNAs. (d) GOTOOLBox analysis of 142 genes identified in GoF 
screening. Pathways are presented along with fold change compared to reference; 
colours indicate p-values. (e) Individual validation of genes. Oct4-GFP EpiSCs were 
transfected with dCas9:SAM and single sgRNAs for 54 genes including Nanog and 
Oct4 and reprogrammed in 2i/LIF for up to 16 days. The number of Oct4-GFP+ iPSC 
colonies were counted (mean of triplicates ± s.d). 
Figure 2 | Sall1 and Nanog reprogram EpiSC and influence ESC differentiation 
(a) Reprogramming efficiencies of Sall1, Nanog and Oct4. Oct4-GFP EpiSCs were 
stably transfected with CRISPRa or cDNA and cultured in 2i/LIF for 16 days without 
selection. Oct4-GFP+ colonies were counted (mean of triplicates ± s.d.) ** p<0.01; 
*** p<0.001; **** p<0.0001. (b) Morphology of Oct4-GFP+ colonies at day 20 in 2i/LIF. 
The reprogrammed colonies are morphologically similar to ESC colonies with Oct4-
GFP+ fluorescence. No colonies were observed in untransfected or mock transfected 
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EpiSCs. (c) RT-qPCR expression profiles of pluripotency markers and EpiSC markers 
in iPSC colonies normalized to Gapdh and relative to ESCs (mean of triplicates ± s.d). 
Cells were transfected with CRISPRa or cDNA as before. (d) Chimeric mouse 
produced with CRISPRa Sall1 – induced PSCs injected into C57B/6 blastocyst. (e) 
Flow cytometric analysis of Rex1-GFP+ cells cultured in EpiSC medium at the 
timepoints indicated. Cells were stably transfected with Sall1 or Nanog cDNA, or 
empty vector and cultured in EpiSC medium (mean of triplicates ± s.d, * p<0.05; 
*** p<0.001, **** p<0.0001 vs. PBCAG:Empty). (f) Number of Rex1-GFP+ ESC 
colonies recovered after ESCs were converted in EpiSC medium at indicated 
timepoints. 600 cells were plated at timepoint zero (mean of triplicates ± s.d., * p< 
0.05; *** p< 0.001, **** p< 0.0001 vs. PBCAG:Empty). 
Figure 3 | CRISPRa gene induction and cDNA mediated overexpression of Sall1, 
Nanog reprogrammed MEF to iPSCs 
(a) (4F+CRISPRa) MEFs were stably transfected with CAG4F and gRNAs against 
Sall1/Nanog/Sall1+Nanog and reprogrammed in ESC medium. Oct4-GFP+ colonies 
were counted after 18 days of reprogramming (mean of triplicates ± s.d., ** p<0.01, 
*** p<0.001). (4F+cDNA) MEFs stably transfected with TRE4F, TRENanog and 
TRESall1 (all co-transfected with PBEF-1αTet3G), induced with 0.5 µg/ml Doxycycline 
for 12 days and counted on day 18 (mean of triplicates ± s.d., ** p<0.01). (b) Alkaline 
phosphatase (AP+) stained ESC colonies reprogrammed from MEFs by 4F alone and 
in combination with Sall1 (induced with Dox at 0.5 µg/ml). (c) iPSCs reprogrammed 
from C57B/6J MEF with 4F/Sall1. Oct4-GFP expression and ESC like morphology 
(upper panel), immunofluorescent staining for pluripotency markers SSEA-1 and 
Nanog (lower panel). (d) In vitro differentiation of C57B/6 MEF reprogrammed iPSCs 
with 4F/Sall1. iPSCs were cultured either in N2B27 for neuronal differentiation, 
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immunofluorescence showed β-Tubulin III+ neuron; or in M10 for mesoderm and 
endoderm differentiation as detected by α-SMA and AFP antibody staining (e) 
Chimeric mice produced with 4F/Sall1-iPSCs injected into CD1 blastocysts. (f) 
Activation of X chromosomes in female 4F/Sall1-iPSCs. iPSCs and the cells 
differentiated from iPSCs were co-immunostained for H3K27me3 and Oct4. Arrows 
indicate H3K27me3 foci. 
Figure 4 | RNA-seq identifies potential mechanisms of reprogramming mediated 
by Sall1 and Nanog 
(a) Venn diagram showing number and percentage of genes being differentially 
expressed in Sall1 and Nanog overexpressing cells with a cut-off padj value < 0.001. 
Upregulated (green arrow) and downregulated (red arrow) genes for further 
experiments were chosen from the overlap between Sall1 and Nanog, except Klf5 and 
Fam189a2. (b) GOTOOLBox analysis of common regulated genes presented along 
with fold change compared to reference. Colours indicate p-values. (c) RT-qPCR 
validations for results obtained from RNA-seq analysis on Sall1 and Nanog 
overexpressing EpiSCs, 24 h after transfection, normalized to Gapdh expression and 
relative to PBCAG:empty (mean of triplicates ± s.d.) (d) Reprogramming of Oct4-GFP 
EpiSCs via CRISPRa mediated gene induction of Klf5, Fam189a2, Tex10 and Tet3. 
After transfection, cells were cultured in 2i/LIF for 20 days and Oct4-GFP+ colonies 
were counted. (mean of triplicates ± s.d.). (e) RT-qPCR expression levels of Klf5, 
Fam189a2, Sall1 and Nanog after CRISPRa mediated gene induction of Klf5 and 
Fam189a2, flow-sorted for sgRNA expression 24 h after transfection, normalized to 
Gapdh and relative to dCas9:SAM (mean of triplicates ± s.d.). (f) RT-qPCR expression 
levels of key regulators in JAK/STAT3 and TGFβ signalling, flow-sorted for sgRNA 
expression 24 h after changing to 2i/LIF media (48 h after transfection), normalized to 
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Gapdh and relative to dCas9:SAM (mean of triplicates ± s.d.). (g) Reprogramming of 
Oct4-GFP EpiSCs via CRISPRa mediated gene induction of Klf5, Fam189a2, Sall1 
and Nanog. After transfection, cells were cultured in 2i/LIF for 20 days and Oct4-GFP+ 
colonies were counted (mean of triplicates ± s.d.). 
Supplementary Figure 1 | Related to main Figure 1: Plasmids used in the study 
LTR: long terminal repeat from HIV-1. PB: PiggyBac inverted terminal repeats to 
enable stable integration by PBase mediated transposition. U6: U6 promoter for 
sgRNA transcription. sgRNA: sgRNA scaffold. sgRNA-MS2-MS2: sgRNA scaffold 
with extended stem loops for dCas9:SAM. PGK: PGK promoter. PuroR: puromycin 
N-acetyltransferase. T2A: 2A peptide from Thosea asigna virus capsid protein. BFP: 
blue fluorescent protein. Poly(A): polyadenylation signal. EF1-α: human elongation 
factor 1 alpha promoter. VP160-dCas9: 10 tandem repeats of transcriptional 
activation domain of herpes simplex virus protein VP16 fused to dCas9. mCherry: 
mCherry fluorescent protein. P2A: 2A peptide from porcine teschovirus-1 polyprotein. 
BlastR: Aspergillus terreus blasticidin S deaminase. GCN4: GCN4 single chain 
antibody. VP64: 4 tandem repeats of transcriptional activation domain of herpes 
simplex virus protein VP16. dCas9-SunTag: GCN4 peptide fused to dCas9. dCas9-
VPR: VP64, P65 and RTA (transcriptional activation domain from the human 
herpesvirus 4) fused to dCas9. MS2: bacteriophage MS2 coat protein. P65: C-terminal 
portion of the p65 subunit of mouse NF-κB. HSF1: C-terminal activation domain from 
the human heat shock transcription factor. E2A: 2A peptide from equine rhinitis A virus 
polyprotein. bpA: bovine growth hormone polyadenylation signal. CAG: CMV 
enhancer, chicken β-actin and rabbit β-globin promoter. TRE: tet response element. 
TET3G: Tet-On-3G transactivator protein. 
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Supplementary Figure 2 | Related to main Figures 1 and 2: Supplementary 
results for GoF CRISPRa screen and gene dosage of Oct4  
(a) Flow cytometry plots showing dynamics of GFP expression in Oct4-GFP reporter 
EpiSCs during reprogramming: Oct4-GFP EpiSCs transfected with dCas9:SAM + 
sgRNA against gene Nanog, dCas9:SAM only or untransfected. Over a time course 
of 14 days in selective 2i/LIF medium, the GFP positive cell population rapidly and 
completely disappears in the untransfected or dCas9:SAM only groups. However, cells 
reprogrammed by CRISPRa mediated overexpression of Nanog recover their Oct4-
GFP levels by day 14. (b) Flow cytometry plots showing the percentage of BFP+ cells 
obtained upon transducing Oct4-GFP EpiSCs with lentiviral sgRNA library at an MOI 
of 0 (untransduced) and an MOI of 0.3. (c) RT-qPCR on Oct4-GFP EpiSCs transfected 
with CRISPRa and cDNA Oct4 showing levels of total Oct4 in cells after 3 days in 
2i/LIF. Levels of Oct4 are normalized to Gapdh (mean of triplicates ± s.d.). (d) Western 
blot on Oct4-GFP EpiSCs transfected with CRISPRa and cDNA Oct4 showing levels 
of total Oct4 in cells after 3 days in 2i/LIF (top panel). Western blot for Oct4 in gRNA 
and CAG cDNA transfected EpiSCs with a comparison to ESCs (bottom panel) Gapdh 
was used as loading control in both cases. (e) Umodl1 regulates re-programming 
pathways: RT-qPCR expression levels of key regulators in JAK/STAT3 and TGFβ 
signalling, on flow-sorted for sgRNA expression either 24 h after transfection (EpiSC 
media) or 24 h after changing to 2i/LIF media (48 h after transfection), normalized to 
Gapdh and relative to dCas9:SAM (mean of triplicates ± s.d.).(f) Variable gene dosage 
with tiled guides: Oct4-GFP EpiSCs were transfected with dCas:SAM and all tiled 
sgRNAs for Sall1 and Nanog available in our library. Numbers on top of bars indicate 
distance to the transcription start site (TSS). (g) RT-qPCR shows that Sall4 is not 
overexpressed when Oct4-GFP+ve EpiSC are transfected with Sall1 CRISPRa.  
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Supplementary Figure 3 | Related to main Figure 2: Reprogramming in Nanog-
GFP reporter EpiSCs and supplementary results for ESC to EpiSC conversion 
(a,b) Gene induction of Sall1, Nanog and Oct4 in Oct4-GFP EpiSC (a) and Nanog-
GFP EpiSCs (b), respectively, with CRISPRa (single sgRNA per target) as well as 
cDNA mediated overexpression in Nanog-GFP EpiSCs. Expression levels were 
measured by RT-qPCR 72h after transfection and expressed in relation to 
dCas9:SAM-only or empty vector (mean of triplicates ± s.d). (c) Reprogramming 
efficiencies of Sall1, Nanog and Oct4. Nanog-GFP EpiSCs were stably transfected 
with CRISPRa or cDNA and cultured in 2i/LIF for 16 days without selection. Nanog-
GFP+ colonies were counted and are represented as mean of triplicates ± s.d. 
** p<0.01; *** p<0.001; **** p<0.0001. (d) RT-qPCR expression profiles of 
pluripotency markers and EpiSC markers in iPSC colonies normalized to Gapdh and 
relative to ESCs (mean of triplicates ± s.d). Cells were transfected with cDNA as 
before. (e) Chimeric mouse produced with cDNA Sall1 – induced PSCs injected into 
C57B/6 blastocyst. (f) Identical endpoints of Oct4-GFP and Nanog-GFP reporter 
EpiSCs in re-programming: Oct4-GFP EpiSCs (top panel) and Nanog-GFP EpiSCs 
(bottom panel) transfected with either dCas9:SAM alone or in combination with 
sgRNAs against Sall1, Nanog and Oct4 and selected in 2i medium in a time course of 
14 and 22 days. As before, Oct4-GFP EpiSCs lose initial GFP expression rapidly and 
recover it upon successful re-programming via CRISPRa mediated gene induction of 
Sall1, Nanog or Oct4, but not in cells transfected with dCas9:SAM only. Nanog-GFP 
reporter EpiSCs – showing no baseline GFP expression – nevertheless upregulate 
GFP with similar but slightly slower dynamics in sgRNA transfected groups only. On 
day 14 both reporter lines show comparable GFP positive cell populations and a clear 
synergistic effect when co-transfecting sgRNAs against Sall1 and Nanog. (g-i) Rex1-
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GFP+ ES cells were stably transfected with Sall1 or Nanog cDNA, or empty vector and 
cultured in EpiSC medium. Change of expression levels of pluripotency marker Rex1 
and differentiation markers Fgf5 and Otx2 measured by RT-qPCR normalized to 
Gapdh expression (mean of triplicates ± s.d) 
Supplementary Figure 4 | Related to main Figures 3 and 4: Sall1 cannot replace 
Oct4 in MEF reprogramming and supplementary results for RNA-seq 
(a) (4F+CRISPRa) MEFs were stably transfected with CAG4F and gRNAs against 
Sall1/Nanog/Sall1+Nanog and reprogrammed in ESC medium. AP+ colonies were 
counted after 18 days of reprogramming. Gene induction of Sall1 produced more iPSC 
colonies compared to CAG4F alone and gene induction of both Sall1 and Nanog 
produced significantly higher number of colonies compared to activation of either Sall1 
or Nanog alone (mean of triplicates ± s.d., ** p<0.01). (4F+cDNA) MEFs stably 
transfected with TRE4F, TRENanog and TRESall1 (all co-transfected with PBEF-
1αTet3G) and induced with 0.5 µg/ml Doxycycline for 12 days. Overexpression of 
Sall1 produced more iPSC colonies compared to CAG4F alone and overexpression 
of both Sall1 and Nanog produced significantly higher number of colonies compared 
to activation of either Sall1 or Nanog alone. AP+ colonies were counted on day 18 
(mean of triplicates ± s.d., *** p<0.001). (b) Morphology of Oct4-GFP+ colonies at 
day 18 in ESC media. The reprogrammed colonies from Oct4-GFP+ MEFs are 
morphologically similar to ESC colonies with Oct4-GFP+ fluorescence. No colonies 
were observed in untransfected or dCas9:SAM only transfected MEFs. (c) MEF were 
stably transfected with CAG4F and TRESall1/PBEF-1αTet3G and reprogrammed in 
ESC medium. 24h after transfection, expression of Sall1 was induced with different 
concentration of Doxycycline for 12 days. After 18 days, both Oct4-GFP+ and AP+ 
colonies were counted. Overexpression of Sall1 produced more iPSC colonies (mean 
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of triplicates ± s.d., ** p<0.01, *** p<0.001, Δ p<0.05, ΔΔ p<0.01 vs. 4F). (d) MEFs 
stably transfected with CAG4F and TRESall1/PBEF-1αTet3G and reprogrammed in 
ESC medium. 0.5 µg/ml Doxycycline was added on the indicated days for the duration 
of reprogramming. Oct4-GFP+ and AP+ colonies were counted on D18 (mean of 
triplicates ± s.d., ** p<0.01, ΔΔΔ p<0.001 vs. 4F). (e-g) MEFs were stably transfected 
with combinations of Oct4, C-myc, Klf4, Sox2 (OCKS) and Sall1 cDNA, whereby Sall1 
replaced either (e) Klf4, (f) Sox2 or (g) Oct4. Cells were reprogrammed in ESC 
medium for 18 days and AP+ colonies were counted (mean of triplicates ± s.d). (h) 
Venn diagram showing number and percentage of genes being differentially 
expressed in Oct4-GFP EpiSC transfected with cDNA for Sall1/Nanog/Sall1+Nanog 
for RNA-seq. Differentially expressed genes were identified with a cut-off padj 
value < 0.001. (i) CAG cDNA mediated overexpression of Sall1, Nanog in Oct4-GFP 
EpiSC transfected with either Sall1/Nanog/Sall1+Nanog for RNA-seq. Expression 
levels were measured by RT-qPCR 48h after transfection and expressed in relation to 
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Supplementary Table 1  
 
Primers for confirming PiggyBac mediated Gene integration (Genotyping) 
 
Gene Name Primer Name Primer Sequence 
Sall1-BPA 
Sall1-BPA F CAATCCTGTCAAGTTCCCAGAAAT 
Sall1-BPA R CATCCCCAGCATGCCTGCTATT 
Nanog-BPA 
Nanog-BPA F AGGGCTATCTGGTGAACGCATC 
Nanog-BPA R AATCCTCCCCCTTGCTGTCCT 
Oct4-c-Myc 
Oct4-c-Myc F GCCCCCAGGTCCCCACTTTG 
Oct4-c-Myc R CCAGCTGATCGGCGGTGGAG 
Klf4-Sox2 
Klf4-Sox2 F ACTATGCAGGCTGTGGCAA 
Klf4-Sox2 R TTGCTGCGGGCCCGGCGGCT 
Tet3G 
Tet3G F CCGTCCAGGCACCTCGATTAGTTC 
Tet3G R GGTATGACTTGGCGTTGTTCC 
Actb 
Actb F GTTTGAGACCTTCAACACCCC 
Actb R GTGGCCATCTCCTGCTCGAAGTC 
gRNA  
pKLV_Flip_gRNA F AGCAAAAAAAGCACCGACTCG 
pKLV_Flip_gRNA R TAAAGCGCATGCTCCAGACTGC 
dCas9:SAM 
SamCas9 F TTACTCAGTTCGTGCTCGTGGAC 
SamCas9 R ATTGCCTTCACGATGAGTTCACA 
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Supplementary Table 2 
Combinations of cDNA transfection used for MEF reprogramming 
 
Constructs Combinations (amount of DNA in µg) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
PBCAG4F 1.0 1.0              
PBCAGCKS       1.0   1.0   1.0   
PBCAGOCK        1.0   1.0   1.0  
PBCAGOCS         1.0   1.0   1.0 
PBCAGOct4          1.0      
PBCAGKlf4            1.0    
PBCAGSox2           0.5     
PBTRE4F   1.0 1.0 1.0 1.0          
PBTRESall1  0.5  0.5  0.5       0.5 0.5 0.5 
PBTRENanog     0.1 0.1          
PBEF1-
αTET3G 
 1.0 1.0 1.0 1.0 1.0       1.0 1.0 1.0 
PiggyBac 
Transposase 
2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
Supplementary Table 2
Supplementary Table 3 
 
Mouse RT-qPCR Probes for RNA Expression 
 







Nanog  Mm02384862_g1 
Pou5f1 Mm00658129_gH 




















Supplementary Table 4 
 












SSEA-1 Clone MC480 BD Pharmingen 560079 1:200 
Nanog Abcam Ab80892 1:150 
β III Tubulin (Tuj1) R & D Systems MAB1159 1:150 
α-Smooth Muscle Actin  R & D Systems MAB1420 1:150 
α-Fetoprotein R & D Systems MAB1368 1:150 
H3K27me3 Millipore 07-449 1:1000 
Oct4 (C10) Santa-Cruz SC-5279 
1:150 (IF) 
1:800 (WB) 
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